Neutralizing ricin

AntoXa is using the vivoXPRESS® system to produce an innovator antibody (PhD9) being studied by Defence Research and Development Canada (DRDC) as an antidote to ricin exposure.

Anti-nerve agents

Countering chemical attacks

AntoXa and the Government of Canada are co-developing butyrylcholinesterase (BuChE) as a next-generation therapeutic and prophylactic countermeasure to organophosphate toxins such as sarin and soman.


Antibodies for Ebola

Antibodies produced using the vivoXPRESS® biopharmaceutical manufacturing system have been shown to neutralize the Sudan strain of Ebola as well as antibodies produced using other systems.